The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations

Cancer

Volumn 82, Issue 8, 1998, Pages 1487-1494

  Iwao, Toshiyasu ^a   Hanada, Keiji ^a   Tsuchida, Akira ^a   Hirata, Manabu ^a   Eguchi, Noriaki ^a   Kajiyama, Goro ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytology; Diagnosis; Endoscopic retrograde cholangiopancreatography; p53 gene mutations; p53 immunocytology; Pancreatic carcinoma; Pancreatic duct brushing

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOMA; PANCREAS CARCINOMA; PANCREAS DUCT; PAPANICOLAOU TEST; POINT MUTATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOCARCINOMA, PAPILLARY; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATITIS; POINT MUTATION; PREOPERATIVE CARE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032523180     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980415)82:8<1487::AID-CNCR9>3.0.CO;2-6     Document Type: Article

References (25)

1. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7:66-86.
2. Goodale RL, Gajl-Peczalaka K, Dressel T, Samuelson J. Cytologic studies for the diagnosis of pancreatic cancer. Cancer 1981;47:1652-5.
3. Van den Berg FM, Tigges AJ, Schipper MEI, den Hartog-Jagar FCA, Kroes WGM, Walboomers-JM. Expression of the nuclear oncogene p53 in colon tumors. J Pathol 1989; 157:193-9.
4. Suzuki T, Takano Y. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nuclear organizer regions in pancreatic duct cell carcinomas. Jpn J Cancer Res 1993;84:1072-7.
5. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-8.
6. Barket J, Iggo R, Cannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
7. Casey G, Yamanaka Y, Fries H, Kobrin MS, Lopez ME, Buchler M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
8. Dowell SP, Wilson POG, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994;54:2914-8.
9. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane D. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991;338:513-4.
10. Dowell SP, Lane DP, Hall PA. The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology 1994;5:76-81.
11. Ishimaru S, Itoh M, Hanada K, Tsuchida A, Iwao T, Kajiyama G. Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Cancer 1996;77:2233-9.
12. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
13. Digiuseppe JA, Hruban RH, Goodman SN, Polak M, Berg FM, Allison DC, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101:684-8.
14. Japan Pancreas Society, editor. General rules for the study of pancreatic cancer. 4th edition. Tokyo: Kanehara, 1993.
15. Apple SK, Hecht JR, Novak JM, Nieberg RK, Rosenthal DL, Grody WW. Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 1996;105:321-6.
16. Prioleau JBA, Schnitt SJ. p53 antigen loss in stored paraffin slides. N Engl J Med 1995;332:1521-2.
17. van den Berg FM, Baas IO, Polak MM, Offerhaus GJA. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol 1993;142:381-5.
18. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR, et al. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinoma. Lab Invest 1996;74:279-89.
19. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazaki I. P53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 1993;68:399-402.
20. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
21. Redson MS, Caldas C, Seymour AB, Hruban RH, Costa LD, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
22. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-60.
23. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
24. Coulondre C, Miller JH, Farabaugh PJ, Gilbert W. Molecular basis of base substitution hot spots in Escherichia coli. Nature 1978;274:775-80.
25. Rideout WM, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagene in the human LDL receptor and p53 genes. Science 1990;249:1288-90.